Qiagen stock is trading -11.08% below its average target price of $51.26 after marking a 2.8% during today's morning session. Analysts are giving the Large-Cap Biotechnology company an average rating of buy and target prices ranging from $45.0 to $60.0 per share.
Qiagen's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.1%. The stock's short ratio is 3.88. The company's insiders own 2.24% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 87.9%. In conclusion, we believe there is positive market sentiment regarding Qiagen.
Institutions Invested in Qiagen
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Massachusetts Financial Services Co. | 10% | 23,117,292 | $1,053,686,211 |
| 2024-09-30 | Wellington Management Group, LLP | 9% | 21,250,943 | $968,618,020 |
| 2024-09-30 | Vanguard Group Inc | 4% | 8,801,970 | $401,193,808 |
| 2024-09-30 | Amundi | 3% | 5,851,275 | $266,701,125 |
| 2024-09-30 | Blackrock Inc. | 2% | 5,450,980 | $248,455,678 |
| 2024-09-30 | Nuance Investments, LLC | 2% | 4,492,954 | $204,788,851 |
| 2024-09-30 | Bank of America Corporation | 2% | 4,270,201 | $194,635,769 |
| 2024-06-30 | Norges Bank Investment Management | 2% | 4,189,592 | $190,961,611 |
| 2024-09-30 | Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 2% | 4,157,361 | $189,492,521 |
| 2024-09-30 | Earnest Partners LLC | 2% | 3,937,914 | $179,490,127 |
